Clinical trials: Fibrinogen
IUGR, Fetal Growth Retardation
Cardiac Displacement From Third Trimester to Early Childhood
The aim is to increase awareness of the relationship between (IUGR) and cardiac function in the foetus, the development of cardiac function over time after delivery and what significance a possible early disturbed myocardial…
- Conditions
- IUGR, Fetal Growth Retardation, Intrauterine Growth Restriction
- Trial name
- CADETTE (NCT02583763)
- Testing
- Echocardiography, Blood sample
- Where
- 2 sites in Sweden
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- University Hospital, Linkoeping
Systemic Lupus Erythematosus
The Predictive and Prognostic Values of the Fibrinogen to Albumin Ratio and C-reactive Protien to Albumin Ratio in Systemic Lupus Erythematosus Patients
The aim of the study was to study the predictive value of FAR and CAR in order to provide a new predictive biomarkers for the disease activity and prognosis.
- Trial name
- NCT06404723
- Testing
- Fibrinogen to albumin Ratio and C-reactive to Albumin Ratio
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Sohag University
Congenital Fibrinogen Deficiency
Safety and Efficacy of Fibryga in Congenital Fibrinogen Deficiency
Open-label, Uncontrolled, Multicenter Observational Study on the Safety and Efficacy of Fibryga in Congenital Fibrinogen Deficiency
- Trial name
- NCT03793426
- Testing
- Fibryga
- Where
- 4 sites in Czechia, Germany
- Volunteers
- 7 people
- Sponsor
- Octapharma
Fibrinogen Deficiency
Human Fibrinogen - Pharmacokinetics
This study evaluated the single-dose pharmacokinetics of human fibrinogen concentrate and clot strength (maximum clot firmness [MCF]) in subjects with congenital fibrinogen deficiency.
- Trial name
- NCT00496262
- Testing
- Human Fibrinogen Concentrate
- Where
- 15 sites in United States, Italy
- Volunteers
- 15 people
- Sponsor
- CSL Behring
Fibrinogen; Deficiency, Acquired, PHARMACOKINETICS
Pharmacokinetic Model of Fibrinogen Plasma Levels After Fibrinogen Administration
characterize the fibrinogen PK in patients with acquired -chronic (cirrhotic patients) or acute- hypofibrinogenemia (severe trauma or critical haermorrhage), showing endogenous production.
- Trial name
- PKMF (NCT05503498)
- Testing
- DATA RECORDING
- Where
- 2 sites in Spain
- Volunteers
- 200 people
- Sponsor
- Hospital Clinic of Barcelona
Unspecified Childhood Solid Tumor, Protocol Specific
Cixutumumab and Temsirolimus in Treating Younger Patients With Solid Tumors That Have Recurred or Not Responded to Treatment
This phase I trial is studying the side effects and best dose of cixutumumab when given together with temsirolimus in treating younger patients with solid tumors that have recurred or not responded to treatment.
- Trial name
- NCT00880282
- Testing
- cixutumumab, temsirolimus, pharmacological study
- Where
- 23 sites in United States, Canada
- Volunteers
- 39 people
- Sponsor
- National Cancer Institute (NCI)
Congenital Heart Disease
Fibrinogen Concentrate vs Cryoprecipitate
One of the most common hemostatic derangements in pediatric open- heart surgery is an acute acquired hypofibrinogenemia. This compromises fibrin clot generation and platelet aggregation, resulting in increased bleeding and…
- Trial name
- NCT03014700
- Testing
- Fibrinogen Concentrate, Cryoprecipitate
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Stanford University
Scoliosis; Adolescence, Bleeding
The Effects of Fibrinogen Concentrate Infusion on Blood Loss and Allogeneic Blood Conservation in Scoliosis Surgery
Allogeneic blood products transfusions are often necessary to treat perioperative bleeding in patients undergoing complex scoliosis surgeries.
- Conditions
- Scoliosis; Adolescence, Bleeding, Surgery
- Trial name
- NCT03183479
- Testing
- Fibrinogen Concentrate Human, Normal saline
- Where
- China
- Volunteers
- 102 people
- Sponsor
- Peking Union Medical College Hospital
Hyperinsulinism
Dose Ranging Study of Recombinant Human Insulin-like Growth Factor I in Children With Hyperinsulinism
OBJECTIVES: I. Determine the dose of recombinant human insulin-like growth factor I that minimizes or decreases the need for exogenous glucose support without causing hypoglycemia.
- Trial name
- NCT00004699
- Testing
- insulin-like growth factor I
- Volunteers
- 8 people
- Sponsor
- Children's Hospital of Philadelphia
Multiple Myeloma, Hematologic Diseases
Multiple Myeloma Prognostic Indices
The aim of this study was to evaluate the impact of albumin / fibrinogen ratio, blood viscosity and RDW on the prognosis of a newly diagnosed MM patients
- Trial name
- NCT06095752
- Testing
- blood viscosity , albumin / fibrinogen ratio and red cell distribution
- Where
- Egypt
- Volunteers
- 48 people
- Sponsor
- Assiut University
Congenital Afibrinogenemia, Hypofibrinogenemia
FIB Grifols Congenital Deficiency for On-demand Treatment and Surgical Prophylaxis
This is a phase 3, multi-center, prospective, open-label, single-arm, clinical trial to be carried out in subjects with congenital fibrinogen deficiency manifested as afibrinogenemia or severe hypofibrinogenemia.
- Trial name
- NCT04636268
- Testing
- FIB Grifols
- Sponsor
- Instituto Grifols, S.A.
Congenital Afibrinogenemia, Congenital Hypofibrinogenemia
Pharmacokinetic, Efficacy and Safety of BT524 in Patients With Congenital Fibrinogen Deficiency
This was a prospective, open-label, multicenter, phase I/III study investigating the 14-day single-dose pharmacokinetic and pharmacodynamic properties, efficacy and safety of BT524 following intravenous administration in the…
- Trial name
- NCT02065882
- Testing
- BT524 (Part I), BT524 (Part II)
- Where
- 6 sites in Bulgaria, Egypt and 3 more
- Volunteers
- 67 people
- Sponsor
- Biotest
Bleeding, Cardiac Defect
ZEPLAST- PED: ZEro_PLASma Trial in Small Infants Undergoing Cardiac Surgery
In pediatric patients (newborns and infants weighing less than 10 kg) undergoing cardiac surgery with extracorporeal circulation postoperative bleeding represents a known complication with a significant impact on outcome.
- Conditions
- Bleeding, Cardiac Defect, Surgery--Complications, Fibrinogenopenia; Acquired
- Trial name
- ZEPLAST-PED (NCT04434001)
- Testing
- Fibrinogen Concentrate Human, Prothrombin Complex Concentrate, Fresh Frozen Plasma
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- IRCCS Policlinico S. Donato
Hyperinsulinism
Short Term Study of Recombinant Human Insulin-like Growth Factor I in Children With Hyperinsulinism
OBJECTIVES: I. Confirm the inhibitory effect of recombinant human insulin-like growth factor I (IGF-I) on insulin secretion in children with hyperinsulinism. II.
- Trial name
- NCT00004825
- Testing
- recombinant human insulin-like growth factor I
- Volunteers
- 10 people
- Sponsor
- FDA Office of Orphan Products Development
C.Surgical Procedure; Cardiac, Blood Coagulation Disorders
Fibrinogen Concentrate In Children Cardiac Surgery 2
The purporse of this study is evaluate whether fibrinogen concentrate reduces postoperative bleeding in pediatric cardiac surgery with cardiopulmonary by-pass.
- Conditions
- C.Surgical Procedure; Cardiac, Blood Coagulation Disorders, Hypofibrinogenemia
- Trial name
- FiCCS2 (NCT03884725)
- Testing
- Fibrinogen Concentrate, control
- Where
- Brazil
- Volunteers
- 42 people
- Sponsor
- Filomena R B G Galas
Sarcoma
Biomarker in Tumor Tissue Samples From Patients With Rhabdomyosarcoma
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT01365962
- Testing
- gene expression analysis, immunohistochemistry staining method, laboratory biomarker analysis
- Volunteers
- 60 people
- Sponsor
- Children's Oncology Group
Rare Bleeding Disorders
Rare Bleeding Disorders in the Netherlands
Rationale: Rare bleeding disorders (deficiency of fibrinogen, factor II, V, V\&VIII, VII, X, XI, XIII, α2-antiplasmin or plasminogen activator inhibitor 1) are not well defined with respect to their clinical phenotype, laboratory…
- Trial name
- RBIN (NCT03347591)
- Testing
- WES, Several assays
- Where
- 7 sites in Netherlands
- Volunteers
- 300 people
- Sponsor
- Radboud University Medical Center
Hyperinsulinism
Phase II Long Term, Randomized Study of Recombinant Human Insulin-like Growth Factor I in Children With Hyperinsulinism
OBJECTIVES: Evaluate the safety and efficacy of long term recombinant human insulin-like growth factor I in children with hyperinsulinism.
- Trial name
- NCT00004700
- Testing
- insulin-like growth factor I
- Volunteers
- 16 people
- Sponsor
- Children's Hospital of Philadelphia
Blood Coagulation Disorders, Hemorrhage
Fibrinogen for Treatment of Pediatric Dilutional Coagulopathy. FibPaed Study.
The purpose of this study is to compare two different thromboelastometry (ROTEM) trigger levels for administration of human fibrinogen concentrate (Haemocomplettan P) in the treatment of perioperative dilutional coagulopathy…
- Trial name
- NCT01487837
- Testing
- Human fibrinogen concentrate
- Where
- Switzerland
- Volunteers
- 57 people
- Sponsor
- University Children's Hospital, Zurich
Brain Stem Neoplasms, Glioma
A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Background: IMC-A12 is an experimental substance designed to inhibit a protein called Type I Insulin-Like Growth Factor Receptor (IGF-1R), which can be found on cancer cells and can promote cancer growth.
- Conditions
- Brain Stem Neoplasms, Glioma, Pinealoma
- Trial name
- NCT01182883
- Testing
- IMC-A12, Temsirolimus
- Sponsor
- National Cancer Institute (NCI)